Institute of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Ren Fail. 2012;34(10):1244-51. doi: 10.3109/0886022X.2012.718711. Epub 2012 Sep 25.
To elucidate the relationship of oxidative stress and specificity protein 1 (Sp1) in the process of epithelial-to-mesenchymal transdifferentiation (EMT) and also to investigate the molecular mechanism of protective effect of probucol on the pathogenesis of diabetic kidney disease (DKD).
Thirty male Sprague-Dawley (SD) rats were randomly divided into control group, diabetic group, and diabetic group under probucol therapy (n = 10 per group). The biochemical indicators including 24-h urinary total protein (24-h UTP) excretion, blood glucose (BG), lipids [triglycerides (TGs), total cholesterol (TC)], serum creatinine (Scr), creatinine clearance rate (Ccr), kidney tissue malondialdehyde (MDA) level, and glutathione peroxidase (GSH-Px) activity were assessed in all groups. The renal pathological changes were evaluated by hematoxylin and eosin (HE) and Masson staining. The protein expression of Sp1, α-smooth muscle actin (α-SMA), and E-cadherin was also measured and analyzed by immunohistochemistry and Western blotting.
Compared with the control group, the BG, TC, Scr, 24-h UTP, and MDA level of renal tissue increased significantly and the Ccr reduced in the rats of diabetic group (all p < 0.01). The pathological scores and the expression of Sp1 and α-SMA in renal tissue were up-regulated (p < 0.01) and the expression of E-cadherin was down-regulated significantly in the diabetic animals (p < 0.01). In the diabetic animals treated with probucol, the renal injuries were alleviated (p < 0.01).
Oxidative stress may play an important role in the EMT process of tubular epithelial cells. Probucol could ameliorate renal disease progression in this model of diabetic nephropathy, which might be due to an antioxidant action, down-regulation of Sp1 protein expression, and inhibition of renal tubular EMT.
阐明氧化应激与特异性蛋白 1(Sp1)在上皮间质转化(EMT)过程中的关系,并探讨普罗布考对糖尿病肾病(DKD)发病机制的保护作用的分子机制。
30 只雄性 Sprague-Dawley(SD)大鼠随机分为对照组、糖尿病组和糖尿病组下的普罗布考治疗组(每组 10 只)。评估所有组的生化指标,包括 24 小时尿总蛋白(24-h UTP)排泄、血糖(BG)、血脂[甘油三酯(TGs)、总胆固醇(TC)]、血清肌酐(Scr)、肌酐清除率(Ccr)、肾组织丙二醛(MDA)水平和谷胱甘肽过氧化物酶(GSH-Px)活性。通过苏木精和伊红(HE)和 Masson 染色评估肾脏病理变化。通过免疫组织化学和 Western blot 测定和分析 Sp1、α-平滑肌肌动蛋白(α-SMA)和 E-钙粘蛋白的蛋白表达。
与对照组相比,糖尿病组大鼠的 BG、TC、Scr、24-h UTP 和肾组织 MDA 水平显著升高,Ccr 降低(均 p < 0.01)。糖尿病动物的肾组织病理评分和 Sp1 和 α-SMA 的表达上调(p < 0.01),E-钙粘蛋白的表达显著下调(p < 0.01)。在糖尿病动物中用普罗布考治疗后,肾损伤得到缓解(p < 0.01)。
氧化应激可能在肾小管上皮细胞 EMT 过程中起重要作用。普罗布考可能通过抗氧化作用、下调 Sp1 蛋白表达和抑制肾小管 EMT 来改善该糖尿病肾病模型中的肾脏疾病进展。